Moderate Dose Hydroxyurea for Secondary Stroke Prevention in Children With Sickle Cell Disease in Sub-Saharan Africa

PHASE3CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

January 31, 2017

Primary Completion Date

March 31, 2020

Study Completion Date

March 31, 2020

Conditions
Sickle Cell DiseaseSickle Cell AnemiaStroke
Interventions
DRUG

Moderate Dose Hydroxyurea

Hydroxyurea therapy at 20 mg/kg/day for primary stroke prevention.

DRUG

Low Dose Hydroxyurea

Hydroxyurea therapy at 10 mg/kg/day (range 7 - 15 mg/kg/day) for primary stroke prevention.

Trial Locations (2)

Unknown

Aminu Kano Teaching Hospital, Kano

Murtala Muhammad Specialist Hospital, Kano

All Listed Sponsors
collaborator

Aminu Kano Teaching Hospital

OTHER

collaborator

Murtala Muhammed Specialist Hospital

OTHER

lead

Vanderbilt University Medical Center

OTHER

NCT02675790 - Moderate Dose Hydroxyurea for Secondary Stroke Prevention in Children With Sickle Cell Disease in Sub-Saharan Africa | Biotech Hunter | Biotech Hunter